contraindications administration of intramuscular (IM)/subcutaneous (SC) medroxyprogesterone acetate (DMPA) injection

Last edited 03/2021 and last reviewed 03/2021

Criteria for Exclusion (1):

• Consent not given. 
• Individuals under 16 years of age and assessed as not competent using Fraser Guidelines.
• Individuals 16 years of age and over and assessed as lacking capacity to consent.
• Known or suspected pregnancy.
• Known hypersensitivity to the active ingredient or to any constituent of the product - see Summary of Product Characteristics.
• Unexplained vaginal bleeding suspicious of a serious medical condition.
• Acute porphyria

Cardiovascular Disease

• Current or past history of ischaemic heart disease, vascular disease, stroke or transient ischaemic attack.
• Individuals with multiple risk factors for cardio-vascular disease (such as smoking, diabetes, hypertension, obesity and dyslipidaemias)
• Hypertension with vascular disease.

Cancers

• Current or past history of breast cancer.
• Benign liver tumour (hepatocellular adenoma).
• Malignant liver tumour (hepatocellular carcinoma).

Gastro-intestinal conditions

• Severe decompensated cirrhosis.

Interacting medicines – see current British National Formulary (BNF) www.bnf.org or individual product SPC http://www.medicines.org.uk

Reference:

• Patient Group Direction (PGD) (NHS Specialist Pharmacy Service).Administration of intramuscular (IM) medroxyprogesterone acetate (DMPA) injection . (Accessed 17th March 2021).